annb0t
Top 20
Immutep Limited
Media Release
2nd line NSCLC patients refractory to anti-PD-(L)1 treatment have few therapeutic options, and the addition of efti to pembrolizumab may help these patients by reverting anti-PD-(L)1 therapy resistance 83% of patients that were studied for Tumor Growth Kinetics showed deceleration (50%) in tumour growth or shrinkage (33%) of target lesions Overall Response Rate (ORR) of 8.3% and Disease Control Rate (DCR) of 33% and responses were confirmed and durable with patien...
>>> Read more: Immutep Announces Abstract Accepted for Mini Oral Presentation at ESMOâs European Lung Cancer Congress 2023
Media Release
2nd line NSCLC patients refractory to anti-PD-(L)1 treatment have few therapeutic options, and the addition of efti to pembrolizumab may help these patients by reverting anti-PD-(L)1 therapy resistance 83% of patients that were studied for Tumor Growth Kinetics showed deceleration (50%) in tumour growth or shrinkage (33%) of target lesions Overall Response Rate (ORR) of 8.3% and Disease Control Rate (DCR) of 33% and responses were confirmed and durable with patien...
>>> Read more: Immutep Announces Abstract Accepted for Mini Oral Presentation at ESMOâs European Lung Cancer Congress 2023
